anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. A pharmaceutical composition which comprises: an essentially nonaqueous, liquid concentrate for oral administration comprising an amount of sertraline or a pharmaceutically acceptable salt thereof and one or more essentially nonaqueous pharmaceutically acceptable excipients; wherein at least one of the excipients is liquid. 2. The composition of claim 1 wherein the pharmaceutically acceptable salt of sertraline is the hydrochloride salt or the mesylate salt. 3. The composition of claim 1 wherein the excipients are selected from the group consisting of ethanol, glycerin, polyethylene glycol and propylene glycols. 4. The composition of claim 3 wherein the excipients are ethanol and glycerin. 5. The composition of claim 1 wherein the concentrate comprises sertraline hydrochloride in an amount of about 15 to about 30 mg/ml and wherein the excipients are ethanol and glycerin in an amount of about 8 to about 20% ethanol (by weight) in glycerin. 6. The composition of claim 5 wherein the concentrate further comprises one or more flavoring agents and one or more pharmaceutically acceptable preservatives. 7. The composition of claim 6 wherein the flavoring agents are selected from the group consisting of peppermint, spearmint and menthol; and wherein the preservatives are selected from the group consisting of butylhydroxytoluene, butylated hydroxyanisole, propyl gallate, ascorbic acid, ascorbyl palmitate, sodium metabisulite, sodium bisulfate, sodium thiosulfate, sodium hydroxide, cystiene, ethylenediamine tetraacetic acid or salts thereof, citric acid, triethanolamine, thioglycerol, methylparaben and propylparaben. 8. The composition of claim 7 wherein the flavoring agent is menthol and wherein the preservative is butylhydroxytoluene. 9. The composition of claim 8 wherein each ml of the concentrate comprises about 22.4 mg of sertraline hydrochloride, about 151 mg of ethanol, about 0.50 mg of menthol, about 0.10 mg of butylhydroxytoluene, and about 1011 mg of glycerin. 10. Use of an essentially nonaqueous, liquid concentrate of sertraline or a pharmaceutically acceptable salt thereof of claim 1 to prepare an aqueous solution of sertraline which comprises diluting the concentrate in an aqueous diluent prior to oral administration. 11. The use of claim 10 wherein the pharmaceutically acceptable salt of sertraline is the hydrochloride salt or the mesylate salt. 12. The use of claim 10 wherein the diluent is selected from the group consisting of water, orange juice, ginger ale, lemon-lime soda and lemonade.
The present invention relates to a compound paracetamol and chlorphenamine maleate slow releasing tablet and a preparation method thereof. The tablet is prepared from a tablet core prepared from 30% to 80% of paracetamol, 0.5% to 4% of chlorpheniramine maleate, 2% to 10% of caffeine, 1% to 10% of artificial bezoar, a slow releasing framework material, a lubricator, an adhesive and a flow aiding agent, and a moistureproof film. The slow releasing tablet can effectively overcome the defect of the existing preparation. A novel framework material is used for manufacturing a slow releasing preparation for constantly releasing a medicament. Effective blood medicament concentration in a body can maintain 12 hours. Administration times can be reduced. The tablet is taken twice every day. The slow releasing tablet has the advantages of smooth blood medicament concentration and small side effect.
Sham Comparator: Sham Treatment group or Manual Control Group Patients included in this group will receive Cervical Manual Therapy (25 minutes) plus sham Diaphragmatic Manual techniques (15 minutes). The program will be carried out three times per week lasting four weeks in total. Each session will last about 40 minutes.
For Stent-based Diverting Technique, the small intestine measuring 15 cm from the ileocecal junction was pulled out through the median incision in the lower abdomen. After a length-wise incision was established in the mesenteric margin of the small intestine, the degradable stent was implanted, and the intestine was sutured. Then, the stent was held in place using an external tie around the bowel. Next, a mushroom-like tube (28 Fr) was placed into the intestine proximal (5-10 cm) to the aforementioned stent. The other side of the mushroom-like tube was inserted through the right lower abdominal wall and connected with a drainage bag. An abdominal drainage tube, or an anal tube, if necessary, was inserted in the proper location prior to the closure of the incision and the abdominal cavity. Abdominal X-ray was routinely performed every week to detect stent degradation, and the mushroom-like tube (28 Fr) was removed two days after stent degradation.
Rufinamide is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-Difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide. It has an empirical formula of C 10H 8F 2N 4O and a molecular weight of 238.19. The drug substance is a white, crystalline neutral powder. Rufinamide is slightly soluble in tetrahydrofuran and in methanol, very slightly soluble in alcohol and in acetonitrile, practically insoluble in water. 

  


  


Rufinamide is available for oral administration as a liquid containing rufinamide USP at a concentration of 40 mg/mL. Inactive ingredients include anhydrous citric acid, hydroxyethyl cellulose, methyl paraben, microcrystalline cellulose and carboxymethyl cellulose sodium, orange flavor, poloxamer, potassium sorbate, propylene glycol, propyl paraben, purified water, simethicone emulsion and sorbitol.
Approximately 80 % of patients who survive CA with cardiopulmonary resuscitation are comatose. The longer it lasts, the lower chances of recovery. The evaluation of the neurological prognosis of these patients is an important issue. Indeed, 72% of patients admitted to an intensive care unit after resuscitation from CA will give rise to an ethical discussion with the family. The prognostication strategy is usually based on a multimodal process involving clinical examination, electro-neurophysiological and biological examinations. We plan to study the relevance of early neurological prognostic tests in the aftermath of CA and in particular the most recent techniques such as the use of a clinical score (CAHP for Cardiac Arrest Hospital Prognosis), automated infrared pupillometry (NEUROLIGHT ALGISCAN, IDMED) for pupillary reflex measurement and quantitative analysis of the continuous amplitude-integrated electroencephalogram (aEEG) BRAIN QUICK ICU LINE, MICROMED. These new prognostic criteria for CA (CAHP score, pupillometry and aEEG) developed separately have not yet been integrated into a multimodal strategy.

The goal of this study is to evaluate the performance of CAHP score, infrared automated pupillometry and aEEG to predict as early as 24h from ROSC the neurological prognosis (Cerebral Performance Categories) at hospital discharge.
Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose.
A process for preparing standards and controls for immunoassays employing monoclonal antibodies. Monoclonal antibodies are used to isolate a restricted portion of an antigen containing an epitope that determines the specificity of the monoclonal antibody-antigen reaction so as to distinguish it from the antigen as a whole, following fragmentation of the complex antigen by procedures including proteolysis. Isolated epitopes are attached covalently or by physical adsorption to particles to immobilize and stabilize the epitope. The particles can be composed of iodipamide ethyl ester, polyvinyl chloride, polystyrene and other inert substances and can be chemically activated to improve epitope binding and stability. Experimental details demonstrate the binding of lipoprotein to IDE, polyvinyl chloride and polystyrene and the subsequent reaction of monoclonal antibodies to these particle-stabilized epitopes. This process is useful particularly for measuring the lipoprotein components associated with cholesterol, and includes a monoclonal based immunoassay kit for measuring the lipoprotein components in biological fluids to assess risk related to coronary artery disease complications.
INTRODUCTION: Postoperative pain after thoracic surgery impairs patients' quality of life and increases the incidence of respiratory complications. Optimised analgesia strategies include minimally invasive incisions, regional analgesia and early chest tube removal. However, little is known about the optimal analgesic regimen for uniportal video-assisted thoracoscopic surgery (uVATS).
METHODS AND ANALYSIS: We will conduct a single-centre, prospective, single-blind, randomised trial. The effects of postoperative analgesia will be tested using thoracic paravertebral block (PVB) in combination with patient-controlled intravenous analgesia (PVB+PCIA), erector spinae plane block (ESPB) in combination with patient-controlled intravenous analgesia (ESPB+PCIA) or PCIA alone; 102 patients undergoing uVATS will be enrolled in this study. Patients will be randomly assigned to the PVB group (30 mL of 0.33% ropivacaine with dexamethasone), ESPB group (40 mL of 0.25% ropivacaine with dexamethasone) or control groups. PCIA with sufentanil will be administered to all patients after surgery. The primary outcome will be total opioid consumption after surgery. Secondary outcomes include postoperative pain score; postoperative chronic pain at rest and during coughing; sensations of touch and pain in the chest wall, non-opioid analgesic consumption; length of stay; ambulation time, the total cost of hospitalisation and long-term postoperative analgesia. Adverse reactions to analgesics and adverse events related to the regional blocks will also be recorded. The statisticians will be blinded to the group allocation. Comparison of the continuous data among the three groups will be performed using a one-way analysis of variance to assess differences among the means.
ETHICS AND DISSEMINATION: The results will be published in patient education courses, academic conferences and peer-reviewed journals.
TRIAL REGISTRATION NUMBER: NCT06016777.
Skyla consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The white T-body has a loop at one end of the vertical stem and two horizontal arms at the other end. The reservoir consists of a whitish or pale yellow cylinder, made of a mixture of LNG and silicone (polydimethylsiloxane), containing a total of 13.5 mg LNG. The reservoir is covered by a semi-opaque silicone membrane, composed of polydimethylsiloxane and colloidal silica. A ring composed of 99.95% pure silver is located at the top of the vertical stem close to the horizontal arms and is visible by ultrasound. The polyethylene of the T-body is compounded with barium sulfate, which makes it radiopaque. A monofilament brown polyethylene removal thread is attached to a loop at the end of the vertical stem of the T-body. The polyethylene of the removal thread contains iron oxide as a colorant (see Figure 10). 

The components of Skyla, including its packaging, are not manufactured using natural rubber latex.

Figure 10. Skyla
OBJECTIVES: Neuregulin 1 (NRG1) is a risk gene for schizophrenia and involved in neurodevelopment and synaptic plasticity. Polymorphisms in NRG1 may affect psychotic symptoms in schizophrenia. This study investigated the effects of the single nucleotide polymorphism (SNP) rs6982890 on peripheral plasma NRG1 immunoreactivity, clinical symptoms and cognitive functions in schizophrenia patients.
MATERIAL AND METHODS: We recruited subjects from the Han population of northern China from 2010 to 2022. We first genotyped and analyzed 6 NRG1 SNPS in 1304 patients with schizophrenia and 871 healthy controls. Then, 91 patients with schizophrenia and 40 healthy controls were selected to detect the peripheral plasma NRG1 immunoreactivity by ELISA. Among them, 84 patients were divided into rs6982890 genotypes to analyze the correlation between NRG1 immunoreactivity and clinical symptoms.
RESULTS: Rs6982890 allelic frequencies were statistically significant between patients and controls. Baseline peripheral plasma NRG1 immunoreactivity in patients were significantly lower than controls. NRG1 immunoreactivity in patients were significantly increased after 8 weeks of antipsychotic treatment and significantly correlated with clinical symptoms and cognitive function. Genotyping of patients with SNP rs6982890 indicated NRG1 immunoreactivity in CC genotype increased significantly after treatment, while CT genotype had no significant change. Baseline NRG1 immunoreactivity with the CT genotype were significantly higher than CC genotype.
CONCLUSIONS: NRG1 SNP rs6982890 is significantly associated with schizophrenia in the Han population of northern China, and it may affect the effect of antipsychotic drug treatment by regulating the peripheral plasma NRG1 immunoreactivity.
IMPORTANCE: Necrotizing soft tissue infections (NSTIs) are severe life- and limb-threatening infections with high rates of morbidity and mortality. Unfortunately, there has been minimal improvement in outcomes over time.
OBSERVATIONS: NSTIs are characterized by their heterogeneity in microbiology, risk factors, and anatomical involvement. They often present with nonspecific symptoms, leading to a high rate of delayed diagnosis. Laboratory values and imaging help increase suspicion for NSTI, though ultimately, the diagnosis is clinical. Surgical exploration is warranted when there is high suspicion for NSTI, even if the diagnosis is uncertain. Thus, it is acceptable to have a certain rate of negative exploration. Immediate empirical broad-spectrum antibiotics, further tailored based on tissue culture results, are essential and should be continued at least until surgical debridement is complete and the patient shows signs of clinical improvement. Additional research is needed to determine optimal antibiotic duration. Early surgical debridement is crucial for improved outcomes and should be performed as soon as possible, ideally within 6 hours of presentation. Subsequent debridements should be performed every 12 to 24 hours until the patient is showing signs of clinical improvement and there is no additional necrotic tissue within the wound. There are insufficient data to support the routine use of adjunct treatments such as hyperbaric oxygen therapy and intravenous immunoglobulin. However, clinicians should be aware of multiple ongoing efforts to develop more robust diagnostic and treatment strategies.
CONCLUSIONS AND RELEVANCE: Given the poor outcomes associated with NSTIs, a review of clinically relevant evidence and guidelines is warranted. This review discusses diagnostic and treatment approaches to NSTI while highlighting future directions and promising developments in NSTI management.
The child in the music therapy group will receive a standard antiemetic treatment procedure 15 minutes before the cisplatin infusion. Music therapy will be applied with the start of cisplatin infusion. The song "The Happiest Child", developed by creating rhythms and developed by Fulya Merve KOS, a researcher with a RhythmotherapistTM certificate issued by the Ministry of National Education, will be used in music therapy. The sound will be adjusted to 45 db. The speaker will be placed at the end of the foot, approximately 30 cm from the child's ear, five minutes before the procedure and will be played to the child during the procedure. After the infusion, music therapy will be terminated and the level of nausea, irritability and anxiety will be evaluated with data collection forms.
The invention provides a kind of preparation method of dendrobium candidum shaddock flavor tea, comprise the following steps：S1. dendrobium candidum fresh leaf, airing are harvested；S2. finish；S3. knead；S4. it will cut top cover and center strip out and is dried to moisture weight content in flower-shaped pomelo peel as 30 ~ 45% after shaddock, pomelo peel, which is stitched together, to be remained with 5 ~ 10cm opening in the overall shape of former shaddock and top and form shaddock ped container；Then dendrobium candidum fresh leaf is put into shaddock ped container from opening；S5. drying is until the water content of dendrobium candidum leaf is 8 ~ 10%；S6. shaddock ped container is taken out from drying room, in indoor 3 ~ 5h of placement of ventilation；S7. flavouring, dendrobium candidum shaddock flavor tea is obtained.The present invention sufficiently make use of dendrobium candidum leaf to carry out tea making, have the health-care effects such as significant reducing blood lipid, hypotensive, moistening lung and production of body fluid, also aromatic with strong pomelo fragrant, mouthfeel.
In order to optimize survival after out-of-hospital cardiac arrest, basic life support (BLS) training of lay-person volunteers is essential. Face-to-face training has long been considered the standard, but new training-methods have emerged, of which the Lifesaver VR (developed by the UK Resuscitation Council) app seems promising. It is unknown which training method results in the highest quality of cardiopulmonary resuscitation (CPR). Therefore, we conduct this randomized controlled trial in which subjects will be randomized to either one of the two training methods. Following the training, all participants will undergo CPR-quality testing using certified manikins and blinded assessors.

The present study will be conducted during Lowlands Science, a section of the Lowlands music festival exclusively dedicated to science. Lowlands will be held on August 16-18 of 2019 and over 50.000 attendees are expected.
A 36-year-old woman with a medical history of opioid use disorder and frequent urinary tract infections presented to the ED from her opioid use disorder clinic, where she was found to have an oxygen saturation by pulse oximetry (Spo2) of 82% on room air. Starting 3 days before presentation, the patient's family noted worsening pale complexion and blue lips at rest. These findings of cyanosis had occurred a few times before and always resolved within a couple days without any medical intervention. She had no pulmonary symptoms outside of long-standing dyspnea with moderate exertion when at work or doing chores around the house. Her medications included methadone 160 mg daily, acetaminophen 650 mg nightly as needed, and phenazopyridine 199 mg three times daily as needed for increased urinary frequency and urethral discomfort that lasted a maximum of 4 days at a time. She confirmed she had started taking a new course of phenazopyridine 4 days before presenting to the ED. She had no dietary restrictions, had been eating her normal diet, and lived in a mobile home with her family, two dogs, and a gerbil. The patient reported using less than 10 tobacco cigarettes per day, one marijuana cigarette nightly, and no alcohol or other drugs. She worked in a warehouse stacking prepackaged bread.
The invention discloses a formula of a traditional Chinese medicine for treating diabetic nephropathy. The formula is characterized by involving the following raw materials by weight: 6 parts of astragalus roots, 3 parts of Pseudostellaria heterophylla, 2 parts of angelica, 2 parts of radix rehmanniae, 2 parts of cornus officinalis, 2 parts of Salvia miltiorrhiza, 3 parts of raw coix seeds, 2 parts of earthworm, 2 parts of Poria, and 2 parts of rhizoma alismatis. Directed at qi-yin deficiency, i.e. the traditional Chinese medicinal core pathogenesis of diabetic nephropathy, the formula has the efficacy of supplementing Qi and nourishing Yin, dispersing blood stasis and promoting dieresis, and is suitable for different-stage diabetic nephropathy with the main manifestations of soreness and weakness of waist and knees, weakness all over the body, edema, foaming urine, nausea, skin pruritus, limb numbness or acroanesthesia (or chilling), dark red tongue, thin or greasy tongue coat, thin pulse or rapid pulse and the like. The formula involves simple medicines and can achieve a special effect. Previous long-term clinical practice and scientific research prove that the formula can significantly reduce the urinary protein excretion rate, delay the renal function progress, effectively improve glucolipid metabolism, effectively control blood pressure, improve the quality of life of patients, and greatly decrease kidney disease end point events, and has the advantages of stable long-term effect and good safety.
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety and efficacy of Oxybutynin chloride extended-release tablets (5 to 30 mg/day) was evaluated in 774 adult subjects who participated in five double-blind, controlled clinical trials. In four of the five studies, Oxybutynin chloride IR (5 to 20 mg/day in 199 subjects) was an active comparator. Adverse reactions reported by ≥ 1% of subjects are shown in Table 1.

The discontinuation rate due to adverse reactions was 4.4% with Oxybutynin chloride extended-release tablets compared to 0% with Oxybutynin chloride IR. The most frequent adverse reaction causing discontinuation of study medication was dry mouth (0.7%).

The following adverse reactions were reported by <1% of Oxybutynin chloride extended-release tablets-treated patients and at a higher incidence than placebo in clinical trials: Metabolism and Nutrition Disorders: anorexia, fluid retention; Vascular disorders: hot flush; Respiratory, thoracic and mediastinal disorders: dysphonia; Gastrointestinal Disorders: dysphagia, frequent bowel movements; General disorders and administration site conditions: chest discomfort, thirst.
Prednisolone acetate ophthalmic suspension 1% 6 times daily on Days -1 to 4 and 4 times daily (QID) on Days 5 to 8 of each cycle; Lubricating eye drops QID throughout the entire cycle (doses should follow steroid dosing, when given, by approximately 15 minutes); MIRV 6 milligrams (mg)/kilogram (kg) adjusted ideal body weight (AIBW) every 3 weeks (Q3W) on Day 1 of each cycle. Each cycle length = 21 days.
Only patients with a minimum of 9 clinically diagnosed grade I and II AK lesions of the scalp (according to the classification by Olsen et al. suggesting the existence of field cancerization, are included in the study. All patients are informed about the purpose of the study and gave informed consent before inclusion. The illumination begins 10 min after the application of MAL cream to the treatment area. In this study, the duration of the light exposure is reduced to 35 min to achieve a PpIX-weighted daylight of 4 J/cm2. MAL cream is removed after the illumination procedure leading to an incubation time of 45 min.
PURPOSE:To obtain a carcinostatic agent for treating laryngeal carcinoma by using bleomycin in combination with IFN-alpha. CONSTITUTION:A carcinostatic agent for the treatment of laryngeal carcinoma with bleomycin is produced by using interferon-alpha for improving the activity of the bleomycin as a main component. The IFN-alpha is a glycoprotein having a molecular weight of 15,000-24,000 and containing 165-166 amino acid units. It can be produced either by the cultivation (of leukocyte, lymphoblast, etc.) or by a genetic engineering method provided that the IFN is originated from human being. Bleomycin is a tumoricidal antibiotic separated from the cultured solution of an actinomycete (Streptomyces verticillus B 80-72) and is used in a form of hydrochloride, sulfate or the like. The IFN-alpha and the bleomycin are administered in combination at an amount of preferably 10<4>-10<9>IU/kg/dose and 0.01-50mg/kg/dose, respectively, by intravenous injection, hypodermic injection, intramuscular injection or the like.